Login / Signup

Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis.

Neslihan AkdoganKerem BalanBasak Yalici ArmaganDuygu GülserenSibel Dogan Gunaydin
Published in: Expert review of clinical pharmacology (2024)
PsA presence, previous biologic therapy experience, BMI, and PsO onset age were identified as independent predictors of SEC discontinuation. These findings underscore the importance of personalized treatment strategies for PsO patients receiving SEC therapy.
Keyphrases
  • rheumatoid arthritis
  • prostate cancer
  • body mass index
  • ankylosing spondylitis
  • systemic lupus erythematosus
  • atopic dermatitis
  • disease activity